Impact of Lipodystrophy on the prevalence and components of metabolic syndrome in HIV-infected patients

BMC Infectious Diseases

José Luís Medina¹  António Sarmento³  Esteban Martinez²  Rui Marques⁵  Sandra Xerinda⁵  Ana Cristina Santos⁴  Selma Souto¹  Davide Carvalho¹  Paula Freitas¹ 

[1] Endocrinology, Diabetes and Metabolism Department of Centro Hospitalar São João, E.P.E., University of Porto Medical School, Alameda Hernani Monteiro, 4200 - 319 Porto, Portugal;Infectious Diseases Department, Hospital Clinic, University of Barcelona, C/Villarroel 170, Barcelona 08036, Spain;Infectious Disease Department of Centro Hospitalar São João, E.P.E, University of Porto Medical School, Alameda Hernani Monteiro, 4200 - 319 Porto, Portugal;Clinical Epidemiology, Predictive Medicine and Public Health Department, University of Porto Medical School, Porto, Portugal and University of Porto Institute of Public Health, Alameda Hernani Monteiro, 4200 - 319 Porto, Portugal;Infectious Disease Department of Centro Hospitalar São João, E.P.E., Alameda Hernani Monteiro, 4200 - 319 Porto, Portugal

关键词: HIV infection;    Lipodystrophy;    Cardiovascular Risk;    Metabolic syndrome;   

Others  :  1175603
DOI  :  10.1186/1471-2334-11-246

 received in 2011-02-28, accepted in 2011-09-20,  发布年份 2011

【 摘 要 】

Background

In HIV-infected patients, combination antiretroviral therapy (cART) is associated with clinical lipodystrophy (CL) and metabolic abnormalities (MA). This study aimed to evaluate the prevalence of the metabolic syndrome (MS) and its components, and to determine whether patients with or without CL had a different prevalence of MA.

Methods

We evaluated 345 HIV-infected patients on cART using two different MS definitions (NCEP-ATPIII-2005 and IDF-2005) and the Framingham risk score.

Results

CL was present in 58.7% of the patients. The prevalence of the MS was 52.2% (ATPIII) and 43.2% (IDF), and it was not significantly different between patients with (W) or without (WT) CL, regardless of the definition used (ATPIII WCL 52.9% vs WT CL 51.1%; p = 0.738; IDF WCL 41.3% vs WTCL 46.0%; p = 0.379). Moderate concordance was observed between the 2 definitions (kappa = 0.484; p < 0.001) and after gender stratification there was good concordance in women (kappa = 0.759; p < 0.001). Patients with CL had lower waist circumference and HDL-C and higher triglycerides levels. In women, CL was significantly associated with MS, hypertriglyceridemia and low HDL cholesterol independently of age, cART and BMI. Patients with CL had a significantly higher risk of coronary heart disease at 10 years, measured by the Framingham risk score, than patients without CL. Those with CL and with MS had higher frequencies of moderate and high risk categories than those without MS.

Conclusions

The prevalence of the MS was high in these HIV-infected patients with an age average of 40 years and this finding could explain why HIV patients have an increased risk for cardiovascular disease (CVD).

【 授权许可】

   
2011 Freitas et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Aberg JA: Cardiovascular complications in HIV management: past, present, and future. J Acquir Immune Defic Syndr 2009, 50(1):54-64.
• [2]Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12(7):F51-58.
• [3]Saint-Marc T, Partisani M, Poizot-Martin I, Rouviere O, Bruno F, Avellaneda R, Lang JM, Gastaut JA, Touraine JL: Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000, 14(1):37-49.
• [4]Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288(21):2709-2716.
• [5]Mancia G, Facchetti R, Bombelli M, Polo Friz H, Grassi G, Giannattasio C, Sega R: Relationship of office, home, and ambulatory blood pressure to blood glucose and lipid variables in the PAMELA population. Hypertension 2005, 45(6):1072-1077.
• [6]Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24(4):683-689.
• [7]Kahn R, Buse J, Ferrannini E, Stern M: The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2005, 48(9):1684-1699.
• [8]Greenland P: Critical questions about the metabolic syndrome. Circulation 2005, 112(24):3675-3676.
• [9]Worm SW, Sabin CA, Reiss P, El-Sadr W, Monforte A, Pradier C, Thiebaut R, Law M, Rickenbach M, De Wit S, Lundgren JD, Friis-Moller N: Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study. Diabetes Care 2009, 32(3):474-480.
• [10]Mangili A, Jacobson DL, Gerrior J, Polak JF, Gorbach SL, Wanke CA: Metabolic syndrome and subclinical atherosclerosis in patients infected with HIV. Clin Infect Dis 2007, 44(10):1368-1374.
• [11]Gazzaruso C, Sacchi P, Garzaniti A, Fratino P, Bruno R, Filice G: Prevalence of metabolic syndrome among HIV patients. Diabetes Care 2002, 25(7):1253-1254.
• [12]Jerico C, Knobel H, Montero M, Ordonez-Llanos J, Guelar A, Gimeno JL, Saballs P, Lopez-Colomes JL, Pedro-Botet J: Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care 2005, 28(1):132-137.
• [13]Jacobson DL, Tang AM, Spiegelman D, Thomas AM, Skinner S, Gorbach SL, Wanke C: Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr 2006, 43(4):458-466.
• [14]Estrada V, Martinez-Larrad MT, Gonzalez-Sanchez JL, de Villar NG, Zabena C, Fernandez C, Serrano-Rios M: Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy. Metabolism 2006, 55(7):940-945.
• [15]Wand H, Calmy A, Carey DL, Samaras K, Carr A, Law MG, Cooper DA, Emery S: Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007, 21(18):2445-2453.
• [16]Mondy K, Overton ET, Grubb J, Tong S, Seyfried W, Powderly W, Yarasheski K: Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis 2007, 44(5):726-734.
• [17]Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A: Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 2007, 30(1):113-119.
• [18]Bonfanti P, Giannattasio C, Ricci E, Facchetti R, Rosella E, Franzetti M, Cordier L, Pusterla L, Bombelli M, Sega R, Quirino T, Mancia G: HIV and metabolic syndrome: a comparison with the general population. J Acquir Immune Defic Syndr 2007, 45(4):426-431.
• [19]Adeyemi O, Rezai K, Bahk M, Badri S, Thomas-Gossain N: Metabolic syndrome in older HIV-infected patients: data from the CORE50 cohort. AIDS Patient Care STDS 2008, 22(12):941-945.
• [20]Diehl LA, Dias JR, Paes AC, Thomazini MC, Garcia LR, Cinagawa E, Wiechmann SL, Carrilho AJ: [Prevalence of HIV-associated lipodystrophy in Brazilian outpatients: relation with metabolic syndrome and cardiovascular risk factors]. Arq Bras Endocrinol Metabol 2008, 52(4):658-667.
• [21]Sobieszczyk ME, Hoover DR, Anastos K, Mulligan K, Tan T, Shi Q, Gao W, Hyman C, Cohen MH, Cole SR, Plankey MW, Levine AM, Justman J: Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2008, 48(3):272-280.
• [22]Nicola Squillace GO AR, Chiara Stentarelli, Stefano Zona, Giula Nardini, Barabara Beghetto, Roberto Esposito, Giovanni Guaraldi: Metabolic syndrome in HIV-associated lipodystrophy. HAART and correlated pathologies 2008, 1:35-38.
• [23]Palella F, WZ CH: Correlates of the metabolic syndrome among HIV seropositive and seronegative men in the multicenter AIDS Cohort Study. Denver 2006.
• [24]Lichtenstein KA: Redefining lipodystrophy syndrome: risks and impact on clinical decision making. J Acquir Immune Defic Syndr 2005, 39(4):395-400.
• [25]Bacchetti P, Gripshover B, Grunfeld C, Heymsfield S, McCreath H, Osmond D, Saag M, Scherzer R, Shlipak M, Tien P: Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005, 40(2):121-131.
• [26]Santos AC, Barros H: Impact of metabolic syndrome definitions on prevalence estimates: a study in a Portuguese community. Diab Vasc Dis Res 2007, 4(4):320-327.
• [27]Van Maldergem L, Da Silva H, Freitas P, D' Abronzo FH: Berardinelli-Seip Syndrome: a new Portuguese disease? Eur J Hum Genet 1998, (6):74A.
• [28]Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112(17):2735-2752.
• [29]Alberti KG, Zimmet P, Shaw J: The metabolic syndrome--a new worldwide definition. Lancet 2005, 366(9491):1059-1062.
• [30]Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97(18):1837-1847.
• [31]Carr A, Samaras K, Chisholm DJ, Cooper DA: Abnormal fat distribution and use of protease inhibitors. Lancet 1998, 351(9117):1736.
• [32]Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA: Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353(9170):2093-2099.
• [33]Carr A, Samaras K, Chisholm DJ, Cooper DA: Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998, 351(9119):1881-1883.
• [34]Capeau J, Magre J, Lascols O, Caron M, Bereziat V, Vigouroux C: [Primary lipodystrophies]. Ann Endocrinol (Paris) 2007, 68(1):10-20.
• [35]Garg A: Acquired and inherited lipodystrophies. N Engl J Med 2004, 350(12):1220-1234.
• [36]Mallon PW, Unemori P, Sedwell R, Morey A, Rafferty M, Williams K, Chisholm D, Samaras K, Emery S, Kelleher A, Cooper DA, Carr A: In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J Infect Dis 2005, 191(10):1686-1696.
• [37]Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, Thiebaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD: Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003, 349(21):1993-2003.
• [38]Grinspoon S, Carr A: Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005, 352(1):48-62.
• [39]Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287(3):356-359.
• [40]Amorosa V, Synnestvedt M, Gross R, Friedman H, MacGregor RR, Gudonis D, Frank I, Tebas P: A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr 2005, 39(5):557-561.
• [41]Ena J, Benito C, Llacer P, Pasquau F, Amador C: [Abnormal body fat distribution and type of antiretroviral therapy as predictors of cardiovascular disease risk in HIV-infected patients]. Med Clin (Barc) 2004, 122(19):721-726.
• [42]De Socio GV, Parruti G, Quirino T, Ricci E, Schillaci G, Adriani B, Marconi P, Franzetti M, Martinelli C, Vichi F, Penco G, Sfara C, Madeddu G, Bonfanti P: Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: results from the SIMONE study. J Infect 2008, 57(1):33-40.